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AbstrAct
Background Central nervous system (CNS) involvement 
contributes to significant morbidity and mortality in 
patients with human epidermal growth factor receptor 
2 (HER2)-positive metastatic breast cancer (mBC) and 
represents a major challenge for clinicians. Liquid 
biopsy of cerebrospinal fluid (CSF)-derived circulating 
tumour DNA (ctDNA) harbours clinically relevant genomic 
alterations in patients with CNS metastases and could be 
effective in tracking tumour evolution.
Methods In a HER2-positive mBC patient with brain 
metastases, we applied droplet digital PCR (ddPCR) and 
next-generation whole exome sequencing (WES) analysis 
to measure ctDNA dynamic changes in CSF and plasma 
collected during treatment.
Results Baseline CSF-derived ctDNA analysis revealed 
TP53 and PIK3CA mutations as well as ERBB2 and cMYC 
amplification. Post-treatment ctDNA analysis showed 
decreased markers level in plasma, consistent with 
extra-CNS disease control, while increased in the CSF, 
confirming poor treatment benefit in the CNS.
Discussion Analysis of ctDNA in the CSF of HER2-positive 
mBC is feasible and could represent a useful companion 
for clinical management of brain metastases.
IntRoDuctIon
Survival of patients with metastatic, 
human epidermal growth factor receptor 
2 (HER2)-positive breast cancer has been 
considerably extended due to the intro-
duction of HER2-directed therapies such 
as the monoclonal antibodies trastuzumab 
and pertuzumab, the antibody-drug conju-
gate trastuzumab emtansine (T-DM1) 
and the tyrosine-kinase inhibitor lapat-
inib.1 Unfortunately, HER2-positive breast 
cancer cells have tropism for the central 
nervous system (CNS), which is consid-
ered a sanctuary site where the activity 
of current anti-HER2 treatment is subop-
timal.2 3 Consequently, although the 
most common initial clinical presenta-
tion of metastatic HER2-positive breast 
cancer is with extra-CNS metastases (ie, 
lung and liver), CNS progression occurs 
in a substantial proportion of patients 
during the course of the disease.4 As a 
matter of fact, enhanced and prolonged 
extra-CNS disease control, achieved by 
HER2 targeting, results in high incidence 
of CNS progression. This occurrence, 
that here we call ‘neurosystemic dissoci-
ation’ of HER2-positive metastatic breast 
cancer (mBC), remains a major challenge 
for medical oncologists, and research is 
striving to find strategies to prevent overt 
CNS metastases or to treat them more 
effectively.5 Markers that could allow early 
diagnosis and treatment of this disease 
are mandatory. Liquid biopsy is a mini-
mally invasive procedure that allows the 
identification and analysis of circulating 
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Key questions
What is already known about this subject?
Cerebrospinal fluid (CSF)-derived circulating tumour 
DNA (ctDNA) harbours clinically relevant genomic 
alterations in breast cancer patients with central 
nervous system (CNS) metastases and could be 
effective in tracking tumour evolution in the CNS (liquid 
biopsy).
What does this study add?
In this clinical case, ctDNA dynamic changes in plasma 
and CSF were more informative than traditional 
imaging in monitoring the disease. Furthermore, ctDNA 
from the CSF provided hints on potential biomarkers of 
CNS metastatisation.
How might this impact on clinical practice?
Paired plasma and CSF-based liquid biopsy could be 
useful to optimise the management of women with 
metastatic, human epidermal growth factor receptor 
2-positive breast cancer who often show differential 
treatment benefits in CNS and extra-CNS sites.
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Figure 1 (A) Timeline of the patient’s clinical events and interventions. (B) H&E of ductal non-special type (NST) (I) and 
micropapillary (V) components of the primary mixed invasive breast cancer. Immunostaining: Oestrogen and progesterone 
receptors are positive in about 10% of the nuclei of ductal NST (II and III) and in 70% (VI) and 40% (VII) of micropapillary 
subtype respectively. HER2 immunostaining is intense and complete (score 3+) in both histotypes (IV, VIII). (C) H&E staining of 
cell block section of fine needle aspiration (FNA) of supraclavicular lymph node showing micropapillary (blue) and glandular 
structures (yellow). (D) ERBB2 gene amplification by FISH in breast cancer cells. Red dots indicate the ERBB2 gene probe, 
and green signals represent the CEP17 reference probe. Magnification: 100x. (E) ddPCR analysis of matched plasma and 
CSF-derived ctDNA prior to T-DM1 treatment. BC, breast cancer; BSC, best supportive care; CSF, cerebrospinal fluid; 
ctDNA, circulating tumour DNA; EC-P, Epi-doxorubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 q21 days for four cycles 
followed by paclitaxel 175 mg/m2 q21days for four cycles; FFPE, formalin fixed, paraffin embedded; FISH, fluorescence in situ 
hybridisation; HERLAP, HERceptin or LAPatinib trial; OFS, ovarian function suppression; PD, progressive disease; RT, radiation 
therapy; T-DM1, trastuzumab emtansine; CNV, copy number variation. 
tumour-derived DNA (ctDNA) that is shed from 
tumour cells in body fluids.6 7 Here we describe a 
clinical case of HER2-positive mBC patient with a 
‘neurosystemic dissociation’ documented by paired 
ctDNA analysis in the cerebrospinal fluid (CSF) and 
in the plasma, and we discuss the potentialities of 
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Figure 2 (A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment. Only point mutations reported in COSMIC 
database are shown (left panel) together with complete copy number profile (right panel). (B) MYC gene amplification by 
fluorescence in situ hybridisation (FISH). Multiple red signals relative to MYC gene are present in breast cancer nuclei. 
Magnification: 100x. CSF, cerebrospinal fluid; ctDNA, circulating tumour DNA; FISH, fluorescence in situ hybridisation; PBMC, 
peripheral blood mononuclear cells; T-DM1, trastuzumab emtansine; WES, whole exome sequencing.
this approach in the management of patients with 
HER2-positive breast cancer. 
MetHoDs
study oversight
The patient provided informed consent for an institu-
tional review board-approved protocol for longitudinal 
collection of plasma and CSF and genomic profiling on 
tumour DNA.
Plasma and cerebrospinal fluid collection
At least 10 mL of whole blood and 4 mL of CSF were collected 
by blood draw (using EDTA as anticoagulant) and lumbar 
puncture, respectively. Plasma was separated and CSF was 
cleaned within 4 hours through two different centrifugation 
steps (the first at room temperature for 10 min at 1600×g and 
the second at 3000×g for the same time and temperature). 
Plasma and CSF were stored at −80°C until ctDNA extraction.
circulating DnA (ctDnA) isolation
ctDNA was extracted from plasma and CSF using the 
QIAamp Circulating Nucleic Acid Kit (Qiagen) according to 
the manufacturer’s instructions.
Additional and detailed materials and methods are 
provided in online supplementary file 1.
Results
Report of the case
A 32-year-old woman presented in October 2004 with a 
left-sided breast invasive ductal carcinoma (figure 1A). 
Modified radical mastectomy was performed and the 
pathology report documented a stage IIB (pT1c, pN1a), 
poorly differentiated (G3), invasive mixed carcinoma 
(not-special type-40% and micropapillary-60%, figure 1B, 
C) estrogen receptor (ER), progesterone receptor 
(PR) and HER2 positive (figure 1D). Adjuvant therapy 
consisted of anthracycline-taxane-based chemotherapy, 
followed by tamoxifen plus ovarian function suppres-
sion for 5 years. Seven years later, a fine-needle aspiration 
of an enlarged supraclavicular lymph-node confirmed 
breast cancer recurrence, with a cytological (figure 1C) 
and immunophenotypical pattern consistent with that 
of the primary tumour (ER 11%, PR 12%, HER2 3+). 
Restaging by CT scan detected both lung and bone metas-
tases. The patient was treated with a chemo-free approach 
within a phase 2 trial conducted at our institution with 
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Figure 3 Analysis of CSF and plasma-derived ctDNA and primary breast tumours. Heatmap of the non-silent genetic 
alterations (top panel) from each of the specimens collected is shown. Violet-scale colour key for MAFs is shown. 
CSF, cerebrospinal fluid; ctDNA, circulating tumour DNA; MAFs, mutant allelic frequencies; PBMC, peripheral blood 
mononuclear cells.
Trastuzumab (T) single agent, for a total of 51 3-weekly 
doses of T, achieving a partial response as best response.8 
Then, for lung disease progression, she started a first-line 
chemotherapy with docetaxel (75 mg/m2)+T for eight 
cycles and then T maintenance therapy. After 2 years she 
presented with headache, reduced flexion of lower limbs 
and gait disturbance. CT scan showed multiple cerebral 
and cerebellar cortico-subcortical contrast-enhancing 
lesions, compatible with CNS metastases and regrowth of 
bone and lung metastases. She then received whole brain 
radiotherapy (30 Gy/10 fractions) and oral corticoster-
oids. On completion of radiation therapy, she started a 
third-line systemic treatment with capecitabine (2000 mg/
m2, from day 1 to day 14)-lapatinib (1250 mg, every day) 
achieving partial response within 4 months. Nine months 
later, epileptic seizures occurred and a CT scan and MRI 
documented a CNS progression with leptomeningeal 
carcinomatosis. She therefore started a fourth line of treat-
ment with the antibody-drug conjugate T-DM1, which was 
stopped after three cycles for worsening of neurological 
symptoms. At the time of neurological deterioration, MRI 
showed stable disease in the CNS and CT scan showed 
a sustained partial remission in extra-CNS disease sites 
(neurosystemic dissociation). Unfortunately, the patient 
died 20 months after the initial diagnosis of CNS metas-
tases. Since the evidence of CNS progression we collected 
multiple plasma samples and two paired CSF samples 
by lumbar puncture, one before and the other after the 
three cycles with T-DM1.
Molecular-based liquid biopsy analyses
We first analysed CSF ctDNA collected before T-DM1 treat-
ment. Whole exome sequencing (WES) revealed a TP53 
p.R248Q mutation (FA 56.16%), a PIK3CA p.R93W muta-
tion (FA 44.18%), cMYC amplification (3.6X). Positivity 
for HER2 overexpression was confirmed by the detec-
tion of high copy number of the ERBB2 exons (15.2X) 
(figure 2A). MYC amplification was later confirmed by 
FISH analysis (figure 2B).
We next analysed the corresponding primary tumour 
tissue. In both the not-special type and micropapillary 
components, WES analysis confirmed the presence of 
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the TP53 p.R248Q mutation and amplification of ERBB2 
and cMYC (figure 3 and see online supplementary figure 
1). Notably, the PIK3CA p.R93W variant found in the 
CSF was detected only in the micropapillary component 
of the tumour and not in the non-special tumour tissue 
(figure 3 and see online supplementary figure 2).
To describe clonal dynamics in plasma ctDNA collected 
during treatment, we designed ddPCR assays for each 
of the molecular alterations found in CSF and tumour 
tissue. cMYC amplification was not detected in plasma 
ctDNA samples. Conversely, ERBB2 amplification, TP53 
and PIK3CA mutations were detectable at the time of 
concomitant CNS and lung progression (figure 3). Plasma 
ctDNA collected before and after treatment with T-DM1 
showed continuously decreasing ERBB2 levels and TP53 
and PIK3CA frequency of mutations, which was consis-
tent with imaging showing extra-CNS disease control. In 
parallel, CSF genomic profiling recapitulated the clinical 
course of the disease in the CNS, with no benefit from 
T-DM1 treatment. Indeed, CSF-derived ctDNA analysis 
revealed high copy number for MYC and ERRB2 and 
high frequency of mutations for TP53 and PIK3CA at 
both timepoints, confirming a molecular non-response to 
T-DM1 treatment (figure 3).
DIscussIon
This case report underscores the potentialities of CSF-de-
rived ctDNA analysis in the management of patients with 
HER2-positive mBC. The emergence of CNS metastases 
in the context of extracerebral disease control represents 
one of the major challenges for medical oncologists dealing 
with this disease (neurosystemic dissociation). Newer tools 
to personalise and monitor the efficacy of treatments are 
therefore needed in this particular population.
In this clinical case, at the time of the second CSF 
progression, we opted for T-DM1 having the patient 
exhausted other treatment options and because of 
preclinical and clinical data suggesting T-DM1 potential 
activity in CNS metastases.9 10
Although we collected paired blood and CSF ctDNA 
samples over a narrow window in this patient’s medical 
history, we show that CSF ctDNA levels follow tumour 
burden variation, being, in this specific case, even more 
informative and sensitive than traditional imaging. 
Indeed, persistence of high levels of ctDNA in the CSF 
predicted neurological deterioration during T-DM1 
treatment. Conversely, extra-CNS sustained response was 
paralleled by a significant drop of molecular alterations 
detectable in plasma samples, as an effect of the antitu-
mour activity of T-DM1.
An interesting finding of our analyses was that WES of 
CSF detected the repertoire of genetic alterations of this 
patient’s mixed histology tumour, including one mutation 
(PI3KCA p.R93W) which was exclusively present in the 
micropapillary component. We speculate that the micro-
papillary component of her tumour, known for being more 
aggressive than the ductal type,11 may have metastasised 
systemically and in CNS sites. This outlines the potentialities 
of ctDNA analysis of CSF in designing strategies to identify 
subjects at increased risk of CNS involvement. While exome 
sequencing in paired plasma ctDNA failed to identify this 
PIK3CA mutation, the latter could be detected in the base-
line plasma sample by targeted ddPCR.
conclusIon
We report that paired analysis of plasma and CSF ctDNA 
might be useful in the management of women with 
HER2-positive mBC. CSF ctDNA levels follow tumour 
burden variations, being potentially more informative and 
sensitive than traditional imaging. Analysis of CSF ctDNA 
could represent, therefore, a minimally invasive approach 
for monitoring progression and response to treatment of 
CNS lesions, in particular within the ‘neurosystemic disso-
ciation’ phenomenon, which frequently occurs during 
HER2 targeted treatments. Furthermore, next genera-
tion sequencing of CSF ctDNA may be highly sensitive 
in identifying the mutational repertoire of a metastatic 
tumour. This may be valuable in designing tailored treat-
ments for CNS disease, in generating hypotheses on the 
clonal evolution of metastatic disease and in identifying 
molecular markers of CNS-tropism.
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